Elite Pharmaceuticals, Inc. Delays Fourth Quarter and Year End 2019 Earnings Release Date and Conference Call

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Elite Pharmaceuticals, Inc. Delays Fourth Quarter and Year End 2019 Earnings Release Date and Conference Call

NORTHVALE, NJ / ACCESSWIRE / June 14, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB: ELTP), announced today that it has delayed its previously announced earnings release and conference call to allow additional time to complete its Form 10-K for the year ended March 31, 2019. The Company has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission and currently expects to file its Form 10-K within the 15-day extension period.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties. These forward-looking statements are not guarantees of future action or performance. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
[email protected]
www.elitepharma.com

SOURCE: Elite Pharmaceuticals, Inc.



View source version on accesswire.com:
https://www.accesswire.com/548764/Elite-Pharmaceuticals-Inc-Delays-Fourth-Quarter-and-Year-End-2019-Earnings-Release-Date-and-Conference-Call

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).